{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:17:53Z","timestamp":1786119473301,"version":"build-2736575974"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1097\/inf.0b013e3181dffabf","type":"journal-article","created":{"date-parts":[[2010,5,22]],"date-time":"2010-05-22T04:24:11Z","timestamp":1274502251000},"page":"e47-e56","source":"Crossref","is-referenced-by-count":29,"title":["Safety and Immunogenicity of a Booster Dose of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine Coadministered With Measles-Mumps-Rubella-Varicella Vaccine in Children Aged 12 to 16 Months"],"prefix":"10.1097","volume":"29","author":[{"given":"Timo","family":"Vesikari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aino","family":"Karvonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Lindblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiina","family":"Korhonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Lommel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Willems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"Dieussaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lode","family":"Schuerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-36-20210202","first-page":"130","article-title":"Measles vaccines.","volume":"79","year":"2004","journal-title":"Wkly Epidemiol Rec"},{"issue":"RR-4","key":"R2-36-20210202","first-page":"1","article-title":"Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"56","author":"Marin","year":"2007","journal-title":"MMWR Recomm Rep"},{"key":"R3-36-20210202","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/INF.0b013e3180616c8f","article-title":"Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine.","volume":"26","author":"Vesikari","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"R4-36-20210202","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00006454-200003000-00003","article-title":"Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children.","volume":"19","author":"Black","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"R5-36-20210202","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM200102083440602","article-title":"Efficacy of a pneumococcal conjugate vaccine against acute otitis media.","volume":"344","author":"Eskola","year":"2001","journal-title":"N Engl J Med"},{"key":"R6-36-20210202","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00001432-200304000-00009","article-title":"Respiratory infections caused by non-typeable Haemophilus influenzae.","volume":"16","author":"Murphy","year":"2003","journal-title":"Curr Opin Infect Dis"},{"key":"R7-36-20210202","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1128\/IAI.67.6.2746-2762.1999","article-title":"Protection against development of otitis media induced by nontypeable Haemophilus influenzae by both active and passive immunization in a chinchilla model of virus-bacterium superinfection.","volume":"67","author":"Bakaletz","year":"1999","journal-title":"Infect Immun"},{"key":"R8-36-20210202","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/314921","article-title":"Effects on the ciliated epithelium of protein D-producing and -nonproducing nontypeable Haemophilus influenzae in nasopharyngeal tissue cultures.","volume":"180","author":"Janson","year":"1999","journal-title":"J Infect Dis"},{"key":"R9-36-20210202","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S0140-6736(06)68304-9","article-title":"Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study.","volume":"367","author":"Prymula","year":"2006","journal-title":"Lancet"},{"key":"R10-36-20210202","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.1128\/IAI.72.9.5383-5391.2004","article-title":"Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components.","volume":"72","author":"Dagan","year":"2004","journal-title":"Infect Immun"},{"key":"R11-36-20210202","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1586\/14760584.7.1.97","article-title":"Combination vaccines containing DTPa-Hib: impact of IPV and coadministration of CRM197 conjugates.","volume":"7","author":"Dagan","year":"2008","journal-title":"Expert Rev Vaccines"},{"key":"R12-36-20210202","article-title":"Priorix-Tetra\u2122 (Measles, Mumps, Rubella and Varicella Vaccine). Summary of Product Characteristics.","year":"2008"},{"key":"R13-36-20210202","article-title":"ProQuad (Measles, Mumps, Rubella and Varicella Vaccine). Summary of Product Characteristics.","year":"2009"},{"key":"R14-36-20210202","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1097\/INF.0b013e318199f62d","article-title":"Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines.","volume":"28","author":"Chevallier","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R15-36-20210202","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1097\/INF.0b013e318199f8ef","article-title":"Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.","volume":"28","author":"Vesikari","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R16-36-20210202","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1097\/INF.0b013e318199f901","article-title":"The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV\/Hib and poliovirus vaccines: assessment of immunogenicity.","volume":"28","author":"Bermal","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R17-36-20210202","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1097\/INF.0b013e318199f609","article-title":"Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different Neisseria meningitidis serogroup C conjugate vaccines.","volume":"28","author":"Wysocki","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R18-36-20210202","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s00431-007-0506-z","article-title":"Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12\u201323 months.","volume":"166","author":"Zepp","year":"2007","journal-title":"Eur J Pediatr"},{"key":"R19-36-20210202","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1128\/CDLI.8.2.266-272.2001","article-title":"Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay.","volume":"8","author":"Concepcion","year":"2001","journal-title":"Clin Diagn Lab Immunol"},{"key":"R20-36-20210202","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1128\/CVI.13.3.356-360.2006","article-title":"Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera.","volume":"13","author":"Henckaerts","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"R21-36-20210202","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1016\/S0264-410X(03)00230-5","article-title":"Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants.","volume":"21","author":"J\u00f3dar","year":"2003","journal-title":"Vaccine"},{"issue":"Annex 2","key":"R22-36-20210202","first-page":"64","article-title":"Pneumococcal conjugate vaccines. Recommendations for production and control of pneumococcal conjugate vaccines.","volume":"927","year":"2005","journal-title":"WHO Tech Rep Ser"},{"key":"R23-36-20210202","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.vaccine.2004.08.030","article-title":"Booster vaccination with hexavalent DTPa-HBV-IPV\/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV\/Hib + HBV administered separately.","volume":"23","author":"Saenger","year":"2005","journal-title":"Vaccine"},{"key":"R24-36-20210202","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/01.inf.0000195626.35239.58","article-title":"Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.","volume":"25","author":"Knuf","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"R25-36-20210202","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.vaccine.2006.09.060","article-title":"Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses.","volume":"25","author":"Heininger","year":"2007","journal-title":"Vaccine"},{"key":"R27-36-20210202","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4161\/hv.5.1.6369","article-title":"Immunogenicity and reactogenicity of two diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccines administered at 3, 5 and 11\u201312 months of age.","volume":"5","author":"Kilpi","year":"2009","journal-title":"Hum Vaccin"},{"key":"R29-36-20210202","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1097\/INF.0b013e318199f61b","article-title":"Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).","volume":"28","author":"Knuf","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R30-36-20210202","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0264-410X(02)00459-0","article-title":"Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.","volume":"21","author":"Nolan","year":"2002","journal-title":"Vaccine"},{"key":"R31-36-20210202","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s15010-007-6337-z","article-title":"Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.","volume":"35","author":"Goh","year":"2007","journal-title":"Infection"},{"key":"R32-36-20210202","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/INF.0b013e318170bb22","article-title":"Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.","volume":"27","author":"Schuster","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"R33-36-20210202","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.vaccine.2008.10.064","article-title":"Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2\u20136 years primed with measles-mumps-rubella (MMR) vaccine.","volume":"27","author":"Gillet","year":"2009","journal-title":"Vaccine"},{"key":"R34-36-20210202","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.vaccine.2009.02.044","article-title":"Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.","volume":"27","author":"Halperin","year":"2009","journal-title":"Vaccine"},{"key":"R35-36-20210202","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1542\/peds.101.4.604","article-title":"Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants.","volume":"101","author":"Rennels","year":"1998","journal-title":"Pediatrics"},{"key":"R36-36-20210202","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/00006454-199909000-00004","article-title":"Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers.","volume":"18","author":"Shinefield","year":"1999","journal-title":"Pediatr Infect Dis J"},{"key":"R37-36-20210202","first-page":"531","article-title":"Vaccines. 5th ed.","author":"Black","year":"2008"},{"key":"R38-36-20210202","doi-asserted-by":"crossref","first-page":"E62","DOI":"10.1542\/peds.106.5.e62","article-title":"Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination.","volume":"106","author":"Virtanen","year":"2000","journal-title":"Pediatrics"},{"key":"R39-36-20210202","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4161\/hv.2.5.3246","article-title":"Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad).","volume":"2","author":"Kuter","year":"2006","journal-title":"Hum Vaccin"},{"key":"R40-36-20210202","first-page":"353","article-title":"Vaccines. 5th ed.","author":"Strebel","year":"2008"},{"key":"R41-36-20210202","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0264-410X(91)90053-9","article-title":"Adverse events following measles-mumps-rubella and measles vaccinations in college students.","volume":"9","author":"Chen","year":"1991","journal-title":"Vaccine"},{"key":"R42-36-20210202","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1542\/peds.2006-0678","article-title":"Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine.","volume":"118","author":"LeBaron","year":"2006","journal-title":"Pediatrics"},{"key":"R43-36-20210202","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.inf.0000250689.09396.21","article-title":"Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.","volume":"26","author":"Vesikari","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"R44-36-20210202","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1086\/375820","article-title":"Vaccine Adverse Event Reporting System Working Group. Extensive limb swelling after immunization: reports to the Vaccine Adverse Event Reporting System.","volume":"37","author":"Woo","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R45-36-20210202","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1045-1870(03)00033-5","article-title":"Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines.","volume":"14","author":"Rennels","year":"2003","journal-title":"Semin Pediatr Infect Dis"},{"key":"R46-36-20210202","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0140-6736(09)61208-3","article-title":"Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.","volume":"374","author":"Prymula","year":"2009","journal-title":"Lancet"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0b013e3181dffabf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:22:33Z","timestamp":1786040553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006454-201006000-00036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0b013e3181dffabf","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}